For the highly sensitive, molecular detection of SARS-CoV-2, we perform PCR-based, quantitative detection of the pathogen from respiratory swab material seven days a week. Both rapid diagnostics (result approx. 1-2 hours after sample receipt) and stand tests (result approx. 4-6 hours after sample receipt) are available.
Furthermore, we routinely perform quantitative determinations of antibodies against the spike antigen (vaccination success) and the nucleocapsid antigen (serological detection of infection) of SARS-CoV-2.
In research projects, we continue to perform neutralization activity assay against replication-competent variants of SARS-CoV-2 (EU1, as well as variants-of-concern (VoCs) alpha, beta, gamma, delta, and omicron-BA.1, BA.4, BA.5) and other current VoCs or variants-of-interest (VoIs). We also quantify the avidity of anti-spike IgGs to better assess not only the quantity but also the quality of these important antibodies for protection against infection and disease.